Cathie Wood's Ark Invest Continues Buying GeneDx Holdings Stock
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 12 2026
0mins
Should l Buy WGS?
Source: Benzinga
- Buying Signal: Cathie Wood's Ark Invest purchased 79,059 shares of GeneDx Holdings over the last seven trading days, indicating strong confidence in the $2.5 billion market cap diagnostic company, which may attract more investor attention.
- Strong Financial Performance: GeneDx reported fourth-quarter revenue of $121 million, a 27% year-over-year increase, and has beaten analyst earnings estimates for ten consecutive quarters, showcasing its robust market performance and growth potential.
- Optimistic Outlook: The company projects 2026 revenue between $540 million and $555 million, reflecting management's confidence in future growth, particularly in its strategic expansion into prenatal diagnostics.
- Stock Price Volatility: Despite GeneDx's stock being down 37.8% year-to-date in 2026, it has a 52-week trading range of $55.17 to $170.87, indicating mixed market perceptions regarding its long-term potential.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy WGS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on WGS
Wall Street analysts forecast WGS stock price to rise
8 Analyst Rating
7 Buy
1 Hold
0 Sell
Strong Buy
Current: 59.610
Low
155.00
Averages
171.43
High
200.00
Current: 59.610
Low
155.00
Averages
171.43
High
200.00
About WGS
GeneDx Holdings Corp. is a genomics company. The Company operates, through its subsidiary, GeneDx, LLC, which is focused on exome and genome tests that translate complex genomic data into clinical answers that unlock personalized health plans, accelerate drug discovery, and improve health system efficiencies. It operates through GeneDx segment, which primarily provides pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing and, to a lesser extent, data and information services. Exome sequencing test options include XomeDx, XomeDx Plus, and XomeDxXpress. GeneDx genome sequencing evaluates the protein-coding and non-coding regions of an individual’s nuclear genome. GeneDx genome sequencing test options include GenomeSeqDx and GenomeXpress. It offers a menu of targeted variant testing options to meet the needs of families and healthcare providers. Its subsidiary, Fabric Genomics, Inc., specializes in artificial intelligence-powered genomic interpretation.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Cathie Wood's Ark Invest Continues Buying GeneDx Holdings Stock
- Buying Signal: Cathie Wood's Ark Invest purchased 79,059 shares of GeneDx Holdings over the last seven trading days, indicating strong confidence in the $2.5 billion market cap diagnostic company, which may attract more investor attention.
- Strong Financial Performance: GeneDx reported fourth-quarter revenue of $121 million, a 27% year-over-year increase, and has beaten analyst earnings estimates for ten consecutive quarters, showcasing its robust market performance and growth potential.
- Optimistic Outlook: The company projects 2026 revenue between $540 million and $555 million, reflecting management's confidence in future growth, particularly in its strategic expansion into prenatal diagnostics.
- Stock Price Volatility: Despite GeneDx's stock being down 37.8% year-to-date in 2026, it has a 52-week trading range of $55.17 to $170.87, indicating mixed market perceptions regarding its long-term potential.
See More
GeneDx Testing Significantly Reduces Healthcare Costs for Children
- Significant Cost Reduction: The SAVES-Kids study by GeneDx reveals that children undergoing ExomeDx™ and GenomeDx™ testing experience an average healthcare cost reduction of 61% in the 12 months post-testing, decreasing from $130,048 to $50,798 per patient per year, highlighting the substantial financial impact of genomic testing.
- Hospitalization Rates Decline: The study indicates an 80% reduction in hospitalization rates and a 70% decrease in emergency room visits for children with epilepsy post-testing, demonstrating that accurate diagnoses and high-value care effectively lower acute care needs and optimize resource allocation.
- Cost Savings for DD/ID Patients: Children with developmental delay/intellectual disability (DD/ID) show a 19% reduction in healthcare costs in the first year after testing, translating to approximately $9,000 in savings, reflecting better outpatient management and informed treatment decisions, further underscoring the value of genomic testing.
- Healthcare Transformation Catalyst: The findings advocate for whole exome sequencing (WES) and whole genome sequencing (WGS) as first-tier tests, emphasizing that early testing can accelerate the transition from high-cost acute care to more planned outpatient and therapeutic pathways, enhancing overall healthcare system efficiency.
See More
GeneDx Partners with Zevra to Enhance NPC Diagnosis and Treatment
- Genetic Testing Collaboration: GeneDx has partnered with Zevra Therapeutics to launch the ExomeDx genetic testing program aimed at expanding access for suspected Niemann-Pick disease type C patients, thereby accelerating clinical diagnosis and improving accuracy.
- Data-Driven Innovation: By leveraging the GeneDx Infinity dataset, the world's largest rare disease genomic dataset, partners can gain deeper insights into disease biology, thus accelerating the patient journey from diagnosis to treatment, showcasing the real-world impact of genomic insights.
- Strong Financial Performance: Zevra Therapeutics reported fourth-quarter earnings of $0.19 per share, exceeding analyst expectations of $0.05, with sales totaling $34.1 million, surpassing estimates of $28.1 million, indicating robust growth potential in the Niemann-Pick disease treatment sector.
- Strategic Shift: Zevra has relocated its global headquarters to Boston to better access specialized talent and plans to focus on multiple near-term growth opportunities in 2026, aiming to create greater value for the rare disease community and its shareholders.
See More
Cathie Wood Increases Holdings in JOBY, WGS, and DKNG Stocks
- Joby Aviation Investment: Cathie Wood increased her stake in Joby Aviation on Monday, which, despite a market cap nearing $10 billion, reported only $50 million in revenue and a staggering 184 times price-to-revenue ratio, indicating market optimism for its future electric air taxi services.
- GeneDx Growth Potential: Wood's addition to GeneDx Holdings comes as the stock has fallen 45% from its three-month peak, yet the company achieved a 40% revenue increase to $427.5 million last year and is projected to reach profitability next year, showcasing its strong growth potential in genetic sequencing.
- DraftKings Market Performance: Wood is also increasing her investment in DraftKings, which generated $6.1 billion in revenue last year, a 27% increase, and plans to launch a new app integrating all betting services, although analysts forecast a slowdown in revenue growth to 14% over the next two years.
- Investment Strategy Analysis: Cathie Wood's strategy of increasing stakes in these high-growth potential companies reflects her confidence despite market volatility and short-term losses, particularly in the electric aviation and genetic sequencing sectors.
See More
GeneDx Partners with Zevra to Expand Genetic Testing Access
- Launch of Genetic Testing Program: GeneDx has partnered with Zevra Therapeutics to introduce a genetic testing program for Niemann-Pick Disease type C, aimed at providing free ExomeDx™ tests to U.S. patients, thereby accelerating the diagnostic process and improving clinical decision-making.
- Data-Driven Decision Making: The program will incorporate de-identified data into the GeneDx Infinity™ database, facilitating faster diagnoses of Niemann-Pick Disease and enabling patients and providers to make more informed treatment choices, thus enhancing overall healthcare efficiency.
- Enhanced Clinical Support: Through this initiative, eligible patients will receive test results within three weeks, significantly reducing uncertainty for families and ensuring timely access to appropriate treatments through GeneDx's rapid feedback mechanism.
- Strategic Partnership Significance: This collaboration not only highlights Zevra's leadership in the Niemann-Pick Disease space but also underscores the critical importance of precise genetic diagnosis as new treatment options emerge, driving increased attention and resource allocation towards rare diseases.
See More
GeneDx Showcases Leadership in Genomics at ACMG 2026
- Scientific Contributions: GeneDx will present 18 accepted abstracts at the 2026 ACMG Annual Meeting, including three platform presentations and two rapid-fire poster talks, highlighting innovations in genomic sequencing and AI-supported interpretations, underscoring its leadership in rare disease diagnostics.
- Impact of Data Scale: The GeneDx Infinity™ dataset, comprising over one million exomes and genomes, demonstrates deep clinical applications, emphasizing how early genomic testing can shorten diagnostic journeys and reduce healthcare costs, fundamentally transforming patient care.
- AI-Driven Innovations: GeneDx's AI technology plays a crucial role in enhancing variant interpretation and accelerating analysis, with the latest MIMI Ranker tool showing high recall rates across a diverse dataset of 16,000 clinical exomes and genomes, significantly reducing manual review time and improving diagnostic efficiency.
- Clinical Benchmarking Study: Analysis of over 300,000 cases reveals a molecular diagnostic yield of 51.4% for GeneDx's exome and genome testing, providing a significant real-world benchmark for clinical WES/WGS performance and highlighting the importance of context surrounding diagnostic yield data.
See More
Cathie Wood's Ark Invest Continues Buying GeneDx Holdings Stock
- Buying Signal: Cathie Wood's Ark Invest purchased 79,059 shares of GeneDx Holdings over the last seven trading days, indicating strong confidence in the $2.5 billion market cap diagnostic company, which may attract more investor attention.
- Strong Financial Performance: GeneDx reported fourth-quarter revenue of $121 million, a 27% year-over-year increase, and has beaten analyst earnings estimates for ten consecutive quarters, showcasing its robust market performance and growth potential.
- Optimistic Outlook: The company projects 2026 revenue between $540 million and $555 million, reflecting management's confidence in future growth, particularly in its strategic expansion into prenatal diagnostics.
- Stock Price Volatility: Despite GeneDx's stock being down 37.8% year-to-date in 2026, it has a 52-week trading range of $55.17 to $170.87, indicating mixed market perceptions regarding its long-term potential.
See More
GeneDx Testing Significantly Reduces Healthcare Costs for Children
- Significant Cost Reduction: The SAVES-Kids study by GeneDx reveals that children undergoing ExomeDx™ and GenomeDx™ testing experience an average healthcare cost reduction of 61% in the 12 months post-testing, decreasing from $130,048 to $50,798 per patient per year, highlighting the substantial financial impact of genomic testing.
- Hospitalization Rates Decline: The study indicates an 80% reduction in hospitalization rates and a 70% decrease in emergency room visits for children with epilepsy post-testing, demonstrating that accurate diagnoses and high-value care effectively lower acute care needs and optimize resource allocation.
- Cost Savings for DD/ID Patients: Children with developmental delay/intellectual disability (DD/ID) show a 19% reduction in healthcare costs in the first year after testing, translating to approximately $9,000 in savings, reflecting better outpatient management and informed treatment decisions, further underscoring the value of genomic testing.
- Healthcare Transformation Catalyst: The findings advocate for whole exome sequencing (WES) and whole genome sequencing (WGS) as first-tier tests, emphasizing that early testing can accelerate the transition from high-cost acute care to more planned outpatient and therapeutic pathways, enhancing overall healthcare system efficiency.
See More
GeneDx Partners with Zevra to Enhance NPC Diagnosis and Treatment
- Genetic Testing Collaboration: GeneDx has partnered with Zevra Therapeutics to launch the ExomeDx genetic testing program aimed at expanding access for suspected Niemann-Pick disease type C patients, thereby accelerating clinical diagnosis and improving accuracy.
- Data-Driven Innovation: By leveraging the GeneDx Infinity dataset, the world's largest rare disease genomic dataset, partners can gain deeper insights into disease biology, thus accelerating the patient journey from diagnosis to treatment, showcasing the real-world impact of genomic insights.
- Strong Financial Performance: Zevra Therapeutics reported fourth-quarter earnings of $0.19 per share, exceeding analyst expectations of $0.05, with sales totaling $34.1 million, surpassing estimates of $28.1 million, indicating robust growth potential in the Niemann-Pick disease treatment sector.
- Strategic Shift: Zevra has relocated its global headquarters to Boston to better access specialized talent and plans to focus on multiple near-term growth opportunities in 2026, aiming to create greater value for the rare disease community and its shareholders.
See More
Cathie Wood Increases Holdings in JOBY, WGS, and DKNG Stocks
- Joby Aviation Investment: Cathie Wood increased her stake in Joby Aviation on Monday, which, despite a market cap nearing $10 billion, reported only $50 million in revenue and a staggering 184 times price-to-revenue ratio, indicating market optimism for its future electric air taxi services.
- GeneDx Growth Potential: Wood's addition to GeneDx Holdings comes as the stock has fallen 45% from its three-month peak, yet the company achieved a 40% revenue increase to $427.5 million last year and is projected to reach profitability next year, showcasing its strong growth potential in genetic sequencing.
- DraftKings Market Performance: Wood is also increasing her investment in DraftKings, which generated $6.1 billion in revenue last year, a 27% increase, and plans to launch a new app integrating all betting services, although analysts forecast a slowdown in revenue growth to 14% over the next two years.
- Investment Strategy Analysis: Cathie Wood's strategy of increasing stakes in these high-growth potential companies reflects her confidence despite market volatility and short-term losses, particularly in the electric aviation and genetic sequencing sectors.
See More
GeneDx Partners with Zevra to Expand Genetic Testing Access
- Launch of Genetic Testing Program: GeneDx has partnered with Zevra Therapeutics to introduce a genetic testing program for Niemann-Pick Disease type C, aimed at providing free ExomeDx™ tests to U.S. patients, thereby accelerating the diagnostic process and improving clinical decision-making.
- Data-Driven Decision Making: The program will incorporate de-identified data into the GeneDx Infinity™ database, facilitating faster diagnoses of Niemann-Pick Disease and enabling patients and providers to make more informed treatment choices, thus enhancing overall healthcare efficiency.
- Enhanced Clinical Support: Through this initiative, eligible patients will receive test results within three weeks, significantly reducing uncertainty for families and ensuring timely access to appropriate treatments through GeneDx's rapid feedback mechanism.
- Strategic Partnership Significance: This collaboration not only highlights Zevra's leadership in the Niemann-Pick Disease space but also underscores the critical importance of precise genetic diagnosis as new treatment options emerge, driving increased attention and resource allocation towards rare diseases.
See More
GeneDx Showcases Leadership in Genomics at ACMG 2026
- Scientific Contributions: GeneDx will present 18 accepted abstracts at the 2026 ACMG Annual Meeting, including three platform presentations and two rapid-fire poster talks, highlighting innovations in genomic sequencing and AI-supported interpretations, underscoring its leadership in rare disease diagnostics.
- Impact of Data Scale: The GeneDx Infinity™ dataset, comprising over one million exomes and genomes, demonstrates deep clinical applications, emphasizing how early genomic testing can shorten diagnostic journeys and reduce healthcare costs, fundamentally transforming patient care.
- AI-Driven Innovations: GeneDx's AI technology plays a crucial role in enhancing variant interpretation and accelerating analysis, with the latest MIMI Ranker tool showing high recall rates across a diverse dataset of 16,000 clinical exomes and genomes, significantly reducing manual review time and improving diagnostic efficiency.
- Clinical Benchmarking Study: Analysis of over 300,000 cases reveals a molecular diagnostic yield of 51.4% for GeneDx's exome and genome testing, providing a significant real-world benchmark for clinical WES/WGS performance and highlighting the importance of context surrounding diagnostic yield data.
See More
